Itraconazol Al (Itraconazole)

Itraconazole blocks the fungal enzyme lanosterol 14α‑demethylase, preventing the synthesis of ergosterol, an essential component of fungal cell membranes. This disruption compromises membrane integrity, inhibiting fungal growth and leading to the resolution of the infection.

The dosage of Itraconazol Al is individualized by the prescribing clinician according to the infection type, severity, patient weight, age, and renal or hepatic function. Patients should follow the exact regimen provided by their healthcare provider.

Itraconazol Al is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should not be used during pregnancy unless the potential benefit justifies the risk. Breastfeeding is not recommended while taking itraconazole because it may pass into milk.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Itraconazol Al. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and necessary import documentation.

Itraconazol Al offers a broad spectrum of activity against yeasts and molds, often preferred for chronic pulmonary aspergillosis and onychomycosis. Compared with fluconazole, itraconazole has a wider mold coverage but may have more drug‑interaction potential due to CYP3A4 inhibition.

Store Itraconazol Al at ambient temperature, below 25 °C, in its original container. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain its stability and potency.

Itraconazol Al is taken orally, usually with a full glass of water. The tablet or capsule should be swallowed whole and not crushed or chewed unless directed otherwise by a healthcare professional.

Serious risks include hepatotoxicity, severe skin reactions such as Stevens‑Johnson syndrome, congestive heart failure, and QT interval prolongation. Patients should be monitored for signs of liver dysfunction, cardiac symptoms, and skin changes throughout therapy.

Itraconazol Al should be avoided in patients with known hypersensitivity to itraconazole or any azole antifungal, those with uncontrolled heart failure, severe hepatic impairment, or in pregnant women unless the benefit outweighs the risk. Consultation with a healthcare provider is essential before starting therapy.